Short sellers reap over $5 billion on Big Tech bets as AI fears roil market

August 21, 2025

Short sellers reap over $5 billion on Big Tech bets as AI fears roil market

Breaking News

Image source: Adobe Stock

Short sellers betting against some of the market's leading AI stocks potentially made billions as markets slid this week and investors moved away from some of the year's hottest tech trades.

On Wednesday, tech stocks stumbled for a second day, with the tech-heavy Nasdaq Composite’s (^IXIC) 0.7% drop leading declines in the major averages as concerns over the sustainability of the AI boom mounted. The Nasdaq fell 1.5%.

Short sellers, who bet on a company’s stock price going down, have made out handsomely on wagers against a basket of AI-linked companies, reaping $5.6 billion on their positions in the past two trading sessions, according to data from S3 Partners.

It’s been a bit of a rough week for AI stocks. Yahoo Finance reports.

EdgeUp

📊 Stock market today: Dow, S&P 500, Nasdaq stumble in wait for Walmart earnings, Jackson Hole kickoff:

The Dow led US stocks lower before the bell on Thursday, with Walmart (WMT) earnings in focus before the start of the Federal Reserve's closely watched gathering at Jackson Hole.

Dow Jones Industrial Average futures (YM=F) pulled back 0.3%, while those on the S&P 500 (ES=F) moved down roughly 0.2%. Contracts on the tech-heavy Nasdaq 100 (NQ=F) nudged 0.1% lower, as the exodus from tech stocks eased.

Walmart (WMT) earnings in premarket will cap a week of results from retail giants, and investors have high expectations. Earlier this week, Home Depot (HD) and Target (TGT) reported results. Yahoo Finance reports.


💻 The tech trade hits pause ahead of Nvidia earnings:

The tech pullback this week wasn't anywhere close to a Deepseek moment, when investors questioned the long-term viability of Silicon Valley's AI transition after the Chinese company competed favorably with OpenAI at a fraction of the cost.

But Wall Street did hit the brakes, alarmed by a handful of pessimistic headlines amplifying long-standing criticism about ballooning valuations and the costs of the AI boom.

While it's too premature and extreme to forecast a major failure or correction — AI stocks have kept plenty enough gains to keep the S&P 500 in the 6,300s — it's clear that the market is signaling a measure of unease with current measures of success. Yahoo Finance reports.


🏦 Treasury yields inch higher as investors look ahead to Fed Chair Powell’s speech:

U.S. Treasury yields inched higher as investors look ahead to Federal Reserve Chairman Jerome Powell’s speech at the Fed’s annual economic symposium on Friday.

At 7 a.m. ET, the 10-year Treasury yield rose over 1 basis point to 4.308%. The 2-year yield was also one basis point higher at 3.76%.

One basis point is equal to 0.01% and yields and prices move in opposite directions. Investors are keeping an eye on the Fed’s annual meeting in Jackson Hole, Wyoming, where central bankers are gathered to make decisions on future monetary policy.

Powell is set to give a speech on Friday at the meeting, which could offer some insights into the path of interest rates. CNBC reports.


💊 J&J to invest $2 billion to boost US manufacturing as drug tariffs loom:

Johnson & Johnson said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing presence amid looming drug import duties proposed by President Donald Trump's administration.

Major drugmakers, including Eli Lilly and AstraZeneca, have also committed to shell out billions of dollars to scale up their U.S. footprint in response to Trump's efforts, including tariff threats.

Earlier this month, Trump said he plans to impose phased-in tariffs for the pharmaceutical sector, which could start small and eventually rise to 250%. MarketScreener reports.


💉 Riding high on Wegovy, Novo doubled its workforce. Now layoffs loom:

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff numbers over five years.

Now sales are slowing and layoffs loom. Annual reports show that Novo's workforce grew from around 43,260 employees in 2019 to 77,350 by the end of last year - an average of 131 new roles filled each week, far faster than rival Eli Lilly (LLY.N), whose headcount rose from 36,000 to 47,000 over the same period. Reuters reports.


🛒 Walmart hikes sales and earnings outlook even as it says tariff costs are rising:

Walmart on Thursday raised its full-year earnings and sales outlook as its online business posted another quarter of double-digit gains, even as the company said costs are rising from higher tariffs.

The big-box retailer topped Wall Street’s quarterly sales estimates. But the company said it felt pressure on profits for the period, including from some one-time expenses, such as restructuring costs, pricier insurance claims and litigation settlements.

Walmart said it now expects net sales to grow between 3.75% to 4.75% for the fiscal year, up from its previous expectations for 3% to 4%. It raised its adjusted earnings per share outlook slightly to $2.52 to $2.62, up from a prior range of $2.50 to $2.60 per share. CNBC reports.

Top 5 Movers in Early Pre-Market

(All pricing and percent gains are based on Early Pre-Market from 4:00 AM to 7:00 AM Eastern Time)
Benzinga reports.


1) $AEMD: Aethlon Medical
Total gain: +63.96%

2) $APM: Aptorum Group
Total gain: +55.11%

3) $THAR: Tharimmune
Total gain: +44.28%

4) $GRO: Brazil Potash
Total gain: +33.11%

5) $EVOK: Evoke Pharma
Total gain: +28.13%

Yesterday’s Biggest Movers

The closing price of the top three market percent gainers trading near or above $3 on August 20.
Benzinga reports.

*All pricing and percent gains are based on regular market trading hours from 9:30am to 4:00pm Eastern Time

1) $THAR: Tharimmune
Total gain: +207.26%
The company reported positive results from a recent pharmacokinetic simulation of its lead clinical candidate, TH104, a buccal film formulation of nalmefene. Findings support the potential of TH104 as a preventive countermeasure for military personnel and chemical responders at risk of exposure to high-potency opioids, including weaponized fentanyl and its analogues. Benzinga reports.

2) $RCKT: Rocket Pharmaceuticals
Total gain: +29.55%
The company announced that the U.S. Food and Drug Administration has lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. Yahoo Finance reports.

3) $PPCB: Propanc Biopharma
Total gain: +21.25%
The company announced the closing of an underwritten public offering of 1,000,000 shares of its common stock, par value $0.001 per share, at $4.00 per share. The stock began trading on the Nasdaq Capital Market on August 15, 2025, under the ticker symbol “PPCB.” Yahoo Finance reports.

Today’s Notable Earnings

*Estimate and Actual numbers represent Earnings Per Share in US Dollars



WDAY: Workday
2Q 2026
After Market Close
Estimate: 1.590
Actual: N/A

ROST: Ross Stores
2Q 2025
After Market Close
Estimate: 1.530
Actual: N/A


ZM: Zoom Video Communications
2Q 2026
After Market Close
Estimate: 1.130
Actual: N/A

Today’s Economic Dates

Time (ET) | Report | Period

7:30 am - Atlanta Fed President Raphael Bostic speaks
8:30 am - Initial jobless claims - August 16
8:30 am - Philadelphia Fed manufacturing survey - July

Parting Thoughts

“This business is not about investing in great companies; it’s about profiting from inefficiently priced stocks.”

- Michael Lauer

Sourced in:
50 Trading Quotes From Top by Quantified Strategies.

Disclaimer

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas; and TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of the Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF) (collectively the "TradeZero Broker Dealers”) are subsidiaries of TradeZero Holding Corp.

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference. There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors only as the amount you may lose can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses. Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the options disclosure (ODD) at OCC before deciding to engage in options trading.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.